通过perampanel有效治疗NR2F1相关的
Xiao Li1, Kai Gao1, Yutang Li2
1Department of Pediatrics, Peking University First Hospital, Beijing, 100034, China.
Acta epileptologica
|April 11, 2025
概括
佩拉曼奈尔有效控制了Bosch-Boonstra-Schaaf视力缩综合征 (BBSOAS) 相关的发作,这是一种耐药性疾病. 这项研究突出显示,佩拉曼奈尔是NR2F1突变患者有前途的治疗选择.
科学领域:
- 遗传学和神经学 遗传学和神经学
- 罕见疾病 罕见疾病
- 的研究研究.
背景情况:
- NR2F1突变与Bosch-Boonstra-Schaaf视力缩综合征 (BBSOAS) 有关.
- 影响了大约46.7%的BBSOAS患者,呈现为耐药性,并与认知/行为问题相关.
- 关于NR2F1相关的治疗策略和结果的数据有限.
研究的目的:
- 为了呈现BBSOAS相关的新病例.
- 总结所有报告的NR2F1相关病例.
- 探索这种罕见的子类型的有效治疗方案.
主要方法:
- 鉴定了中国的六例性BBSOAS新病例,揭示了五种独特的新型异性NR2F1突变.
- 包括两个新的突变:c.365G>T,p.Cys122Phe和c.449G>T,p.Gly150Val.
- 分析了新病例和14个先前报告的病例 (共20名患者) 的结合分析了特征和治疗结果.
主要成果:
- 在60%的患者中观察到婴儿发作;其他发作类型包括通用性增强性/克隆性,焦点性,肌性和缺席性发作.
- 虽然以前的治疗方法 (药物,类固醇,性饮食) 取得了有限的成功 (50%的控制),但所有6例新病例都通过佩拉曼尼尔补充治疗实现了自由.
- 佩拉曼奈尔表现出迅速的疗效,平均在7.33个月内控制了发作,平均在14个月内持续控制了发作.
结论:
- 这项研究全面描述了NR2F1相关的,详细说明了临床特征,治疗方法和结果.
- 佩拉曼奈尔在治疗NR2F1相关的治疗中显示出显著的疗效,提供了潜在的治疗策略.
- 发现的新突变扩大了BBSOAS和相关的已知基因型谱.
更多相关视频
10:22Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy
Published on: December 6, 2016
20.1K
08:20MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
Published on: August 11, 2015
13.8K
相关概念视频
01:14Antiepileptic Drugs: Glutamate Antagonists
252
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
252
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
190
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
190
01:20Antiepileptic Drugs: Potassium Channel Activators
129
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
129
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
264
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
264
01:08Antiepileptic Drugs: Sodium Channel Blockers
270
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
270
01:17Antiepileptic Drugs: Calcium Channel Blockers
250
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
250